
    
      Subjects will be randomized to one of three treatment sequences. Each sequence will contain
      up to 8 subjects. In each treatment sequence, subjects undergo a baseline/screening period,
      three treatment periods, and a follow-up visit.

      Subjects will be administered a single dose of TT-00420 on Day 1 of either TT-00420 tablet
      under fed condition, TT-00420 tablet under fasting condition, or capsule under fasting
      condition and crossed over after at least a 14-day washout period.
    
  